CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Kuo Hua Tung, Cheng Wei Lin, Chun Chen Kuo, Li Tzu Li, Ya Hsun Kuo, Chung Wu Lin, Han Chung Wu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

Original languageEnglish
Pages (from-to)58-67
Number of pages10
JournalCancer Letters
Volume331
Issue number1
DOIs
Publication statusPublished - Apr 30 2013
Externally publishedYes

Fingerprint

Clathrin Heavy Chains
Vascular Endothelial Growth Factor A
Growth
Neoplasms
Pancreatic Neoplasms
Small Interfering RNA
Vascular Tissue Neoplasms
Protein Stability
Carcinogenesis
Proteins
Adenocarcinoma
Monoclonal Antibodies
Hypoxia
Mortality
Antibodies

Keywords

  • Angiogenesis
  • Clathrin heavy chain
  • HIF-1α
  • Monoclonal antibody
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. / Tung, Kuo Hua; Lin, Cheng Wei; Kuo, Chun Chen; Li, Li Tzu; Kuo, Ya Hsun; Lin, Chung Wu; Wu, Han Chung.

In: Cancer Letters, Vol. 331, No. 1, 30.04.2013, p. 58-67.

Research output: Contribution to journalArticle

Tung, Kuo Hua ; Lin, Cheng Wei ; Kuo, Chun Chen ; Li, Li Tzu ; Kuo, Ya Hsun ; Lin, Chung Wu ; Wu, Han Chung. / CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. In: Cancer Letters. 2013 ; Vol. 331, No. 1. pp. 58-67.
@article{b627b37b551c4648994bc9b67c2f737b,
title = "CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling",
abstract = "Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.",
keywords = "Angiogenesis, Clathrin heavy chain, HIF-1α, Monoclonal antibody, Pancreatic cancer",
author = "Tung, {Kuo Hua} and Lin, {Cheng Wei} and Kuo, {Chun Chen} and Li, {Li Tzu} and Kuo, {Ya Hsun} and Lin, {Chung Wu} and Wu, {Han Chung}",
year = "2013",
month = "4",
day = "30",
doi = "10.1016/j.canlet.2012.12.001",
language = "English",
volume = "331",
pages = "58--67",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

AU - Tung, Kuo Hua

AU - Lin, Cheng Wei

AU - Kuo, Chun Chen

AU - Li, Li Tzu

AU - Kuo, Ya Hsun

AU - Lin, Chung Wu

AU - Wu, Han Chung

PY - 2013/4/30

Y1 - 2013/4/30

N2 - Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

AB - Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.

KW - Angiogenesis

KW - Clathrin heavy chain

KW - HIF-1α

KW - Monoclonal antibody

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84873522077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873522077&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.12.001

DO - 10.1016/j.canlet.2012.12.001

M3 - Article

VL - 331

SP - 58

EP - 67

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -